Clinical review report : indication: the acute, intermittent treatment of "OFF" episodes in patients with Parkinson disease. Apomorphine hydrochloride (Kynmobi) (Sunovion Pharmaceuticals Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Physical Description:

1 online resource (99 pages)

Edition:

Final (with redactions).

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2021.

Summary:

The objective of the current CADTH Common Drug Review was to perform a systematic review of the beneficial and harmful effects of apomorphine hydrochloride sublingual film (Kynmobi) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease.

Contents:

Abbreviations

Executive Summary

Introduction

Stakeholder Engagement

Clinical Evidence

Conclusions

Disease Background

Standards of Therapy

Drug

Patient Group Input

Clinician Input

Systematic Review (Pivotal and Protocol Selected Studies)

Findings From the Literature

Results

Indirect Evidence

Review and Appraisal of ITC

Other Relevant Evidence

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Literature Search Strategy

Appendix 2. Detailed Outcome Data

Appendix 3. Description and Appraisal of Outcome Measures

References.

Notes:

Description based on publisher supplied metadata and other sources.